News Daily News Cada Vez Más Evidencias Confirman que No hay un Mayor Riesgo de Insuficiencia Cardíaca asociado a los Fármacos Antidiabéticos basados en la Incretina Michael O'Riordan March 25, 2016
News Industry News Victoza® Significantly Reduced the Risk of Major Adverse Cardiovascular Events in the LEADER Trial March 06, 2016
News Industry News New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA™ is Well Tolerated and Delivers Sustained 24-hour Antiplatelet Control March 01, 2016
News Industry News Renova Therapeutics expands robust gene therapy intellectual property portfolio for cardiovascular and metabolic disease treatments January 03, 2016
News Industry News Jardiance® (empagliflozin) is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial September 18, 2015
News Conference News ESC 2015 ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff September 09, 2015
News Conference News ESC 2015 Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes Yael L. Maxwell September 01, 2015
News Conference News ESC 2015 Novel Diabetes Drug Shows No Sign of Increasing Events in ACS Patients L.A. McKeown August 31, 2015
News Industry News New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology August 20, 2015
News Daily News Los Niveles Altos de Troponina T Pronostican Malos Resultados en Pacientes Con Diabetes Tipo 2 y Cardiopatía Estable Todd Neale August 17, 2015
News Conference News EuroPCR 2015 Evolving DES Technology May Benefit Diabetic Patients Caitlin E. Cox May 19, 2015
News Daily News Vorapaxar es Eficaz como Prevención Secundaria en Pacientes Diabéticos con Antecedentes de IM L.A. McKeown February 22, 2015
News Daily News Vorapaxar Effective for Secondary Prevention in Diabetic Patients With Prior MI L.A. McKeown February 22, 2015
News Daily News SORT OUT III Substudy Hints at Differences in DES Efficacy Based on Diabetes Status Todd Neale November 17, 2014
News Daily News El Subestudio SORT OUT III Apunta a Diferencias en la Eficacia de los Stents Liberadores de Fármacos (SLF) según el Estado Diabético Todd Neale November 17, 2014